LINCOLN PHARMACEUTICALS LIMITED Lincoln Pharmaceuticals Limited Share Price NSE India S.E.
Equities
LINCOLN
INE405C01035
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 594 INR | -0.48% |
|
+0.56% | -2.53% |
| Sales 2022 | 4.72B 56.6M 4.52B | Sales 2023 | 5.1B 61.18M 4.88B | Capitalization | 6.78B 81.33M 6.49B |
|---|---|---|---|---|---|
| Net income 2022 | 694M 8.32M 664M | Net income 2023 | 729M 8.74M 698M | EV / Sales 2022 | 1.08 x |
| Net cash position 2022 | 1.14B 13.61M 1.09B | Net cash position 2023 | 1.12B 13.41M 1.07B | EV / Sales 2023 | 1.11 x |
| P/E ratio 2022 |
8.98
x | P/E ratio 2023 |
9.31
x | Employees | 1,645 |
| Yield 2022 |
0.48% | Yield 2023 |
0.44% | Free-Float | 44.04% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.48% | ||
| 1 week | +0.56% | ||
| Current month | +1.37% | ||
| 1 month | -0.65% | ||
| 3 months | -8.76% | ||
| 6 months | +19.16% | ||
| Current year | -2.53% |
1 week
589.20
608.35
1 month
558.30623.00
Current year
555.00755.15
1 year
365.25755.15
3 years
255.00755.15
5 years
85.05755.15
10 years
85.05755.15
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 19/01/95 | |
| Director of Finance/CFO | - | 27/03/19 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 19/01/95 | |
| Chairman | 80 | 15/08/95 | |
| Director/Board Member | 66 | 19/01/95 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 594 | -0.48% | 23 219 |
| 26/04/24 | 596.9 | -0.57% | 22,877 |
| 25/04/24 | 600.4 | +1.19% | 18,355 |
| 24/04/24 | 593.3 | -1.08% | 29,475 |
| 23/04/24 | 599.8 | +1.52% | 34,696 |
Delayed Quote NSE India S.E., April 29, 2024 at 12:40 pm
More quotes
Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading of pharmaceuticals products like medicines, injections and other related products. The Companyâs product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, liquid in bott, liquid injection and pharma products. It has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The Company serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The Company's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.
Sector
Pharmaceuticals
Calendar
29/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +26.81% | 661B | |
| +27.35% | 566B | |
| -6.35% | 352B | |
| +20.43% | 332B | |
| +2.63% | 283B | |
| +14.00% | 231B | |
| +5.15% | 200B | |
| -9.04% | 195B | |
| -4.77% | 145B |
- Stock Market
- Equities
- LINCOLN Stock
- LINCOLN Stock
